British-Swedish pharmaceutical and biotechnology company AstraZeneca (LSE:AZN)(STO:AZN) announced on Monday that Tagrisso (osimertinib) has secured European Union approval for treating adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 (L858R) mutations, whose disease remains stable after platinum-based chemoradiation therapy (CRT).

Approval follows a positive opinion from the Committee for Medicinal Products for Human Use and is underpinned by the LAURA Phase III trial results published in The New England Journal of Medicine. The trial demonstrated an 84% reduction in the risk of disease progression or death with Tagrisso versus placebo (hazard ratio 0.16; p